Passive immunotherapy with plasma derived from patients convalescent from SARS-CoV-2
infection can be a promising approach in the treatment of COVID-19 patients. It is important …

Abstract Coronavirus disease 2019 (COVID-19) caused by the novel coronavirus has
become a Public Health Emergency of International Concern. Among the various treatment …

Most high-income countries are aggressively engaged in the collection and research
evaluation of convalescent plasma as a specific passive immunotherapy for treatment of …

Abstract Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), the cause of
coronavirus disease (COVID-19), spreading from Wuhan to worldwide has been emerged …

Objectives The patients with hematological malignancies are a vulnerable group to COVID-
19, due to the immunodeficiency resulting from the underlying disease and oncological …

Every severe viral infection since the Spanish Flu has stimulated interest in passive
immunotherapy, in the absence of antiviral treatment and a vaccine program [1]. The …

There are currently no licensed vaccines or therapeutics for COVID‐19. Anti‐SARS CoV‐2
antibody‐containing plasmas, obtained from the recovered individuals who had confirmed …

The recent coronavirus disease 2019 (COVID-19) epidemic is spreading all over the world.
By March 23, over 300,000 patients had been confirmed and almost 15,000 died because of …

Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory coronavirus 2
(SARS-CoV-2), has rapidly spread since its first declaration by the World Health …

Background/aim: The SARS-CoV-2 infection was declared as a pandemic by the World
Health Organization (WHO) on March 11, 2020, and the death toll from COVID-19, which is …